ARS Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
Mailing Address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
Phone
858-771-9307
Fiscal Year End
1231
EIN
811489190
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 31, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 24, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 10-K Annual financial report | March 9, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 13, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 21, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
Annual Reports
10-K
March 9, 2026
- Neffy achieved its first commercial sale in the U.S. in June 2025, marking ARS Pharmaceuticals' transition to a commercial entity.
- Total revenue significantly increased to $15.5 million, driven by initial Neffy product sales ($8.2 million) and collaboration agreements ($7.3 million).
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.